Ajax Health-backed Ablacon announced that it closed a Series B financing round worth $30 million with a new lead investor.
Zeus Health joined as the new lead investor in the financing, while the company announced that Beaumont Health (Royal Oak, Mich.) Heart Rhythm Center director Dr. David Haines was appointed to Ablacon’s scientific advisory board, according to a news release.
Menlo Park, Calif.-based Ablacon plans to put the new funds toward its product portfolio in an effort to expand patient access to its CE Marked Ablamap system. Part of Haines’ new role on the SAB will be to help map out a clinical research strategy to demonstrate the promise of using the system in treating Afib.
“I’m thrilled to have Zeus Health join Ablacon as we work to bring this game-changing technology to market,” Ablacon CEO Duke Rohlen said in the release. “I welcome Dr. Haines to the team – he is a true innovator in the field of electrophysiology and we are excited to have him join the other thought-leaders on our world-class scientific advisory board.”
“When I was introduced to Ablacon’s Electrographic Flow technology, I was impressed by its novel approach and exciting results,” added Haines. “The technology brings together many of the theories and concepts in the field of electrophysiology and transforms them into an actual product that is intuitive and actionable. I’m looking forward to using the system with my patients when the technology comes to the United States in 2021.”
